|
⚲
|
| Keyboard |
| Suvretta Capital Management LLC
✚
|
|
|---|---|
| CRD # | 165153 |
| SEC # | 801-79962 |
| CIK # | 0001569064 |
| AUM | 7,866.7 M (2026-03-19) |
| Employees | 23 (52% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-702-5200 |
| Address | 540 Madison Avenue New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (7/1/2026) [Brochure] |
|---|
ITEM 5 – Fees and Compensation
The fees applicable to each Fund are set forth in detail in their respective confidential private
placement memorandums. A summary of the fees is provided below.
Montanova and the General Partners typically receive compensation from the Funds in the
form of fees based on a percentage of assets under management and performance-based
incentive allocations.
• The Long-Short Funds pay Montanova a quarterly management fee in advance ranging
from 0% to 1.5% (per annum) of the net assets of the Long-Short Funds. For Long-
Short Fund assets that are Designated Investments, the quarterly management fee is
based upon the lower of (i) initial cost, as adjusted for partial realizations of such
Designated Investment and (ii) fair value (which may be at cost).
• The Averill Funds pay Montanova a quarterly management fee in advance ranging from
1% to 2% (per annum) of the net assets of the Averill Funds. For Averill Fund assets
that are Designated Investments, the quarterly management fee is based upon the
A “SICAV,” which stands for Société d’investissement à capital variable, is a type of open-ended investment
fund with variable share capital that may invest in transferable securities, money market instruments, units of
investment funds, deposits and financial derivative instruments.
lower of (i) initial cost, as adjusted for partial realizations of such Designated
Investment and (ii) fair value (which may be at cost).
• The Madison Funds pay Montanova a quarterly management fee in advance ranging
from 1.5% to 2% (per annum) of the net assets of the Madison Funds. For Madison
Fund assets that are Designated Investments, the quarterly management fee is based
upon the lower of (i) initial cost, as adjusted for partial realizations of such Designated
Investment and (ii) fair value (which may be at cost).
The Funds will also allocate an annual performance allocation to the General Partners as
described below:
The Long-Short Funds Performance Allocation
The GP will receive an annual performance allocation ranging from 0% to 20% of the
net profits (including net unrealized gains) as of the end of each fiscal year (after
deducting all expenses) allocated to an investor, subject to a loss carryforward
provision that is described in the Onshore Fund’s and Offshore Fund’s confidential
private placement memorandums. Net unrealized profits attributable to Designated
Investments are not included in calculating the performance allocation until a
Designated Investment is realized or deemed realized.
The Averill Funds Performance Allocation
The Averill GP will receive an annual performance allocation ranging from 10% to 20%
of the net profits (including net unrealized gains) as of the end of each fiscal year (after
deducting all expenses) allocated to an investor, subject to a loss carryforward
provision that is described in Averill Onshore’s and Averill Offshore’s confidential
private placement memorandums. Net unrealized profits attributable to Designated
Investments are not included in calculating the performance allocation until a
Designated Investment is realized or deemed realized.
The Madison Funds Performance Allocation
The Madison GP will receive an annual performance allocation ranging from 20% of
the net profits generated above the returns of a benchmark return (described below);
to 20% of the net profits (including net unrealized gains) as of the end of each fiscal
year (after deducting all expenses) allocated to an investor, subject to a loss
carryforward provision that is described in Madison Onshore’s and Madison Offshore’s
confidential private placement memorandums. Net unrealized profits attributable to
Designated Investments are not included in calculating the performance allocation
until a Designated Investment is realized or deemed realized.
The benchmark return is calculated as the amount that a capital account or series of
shares (collectively “Capital Accounts”) would have appreciated or declined during a
performance period if it had achieved a rate of return for such period equal to that of
the benchmark specified in the Madison Onshore Fund’s and Madison Offshore Fund’s
confidential offering memorandums.
Because for certain limited partners and/or shareholders the annual performance
allocation is determined based upon a Capital Account outperforming the benchmark
return for any fiscal year, it is possible the Madison GP will be entitled to receive a
performance allocation for a fiscal year even if the Capital Account had depreciated in
value during the year. In addition, it is also possible that the performance allocation
earned by the Madison GP will exceed the Capital Account’s allocable share of net
profits at the Master Fund level in a fiscal year. Under such circumstances, the
performance allocation will be reallocated to the Madison GP for a fiscal year only to
the extent of the Master Fund’s net profits allocated to such Capital Account for such
fiscal year. The remaining portion of the performance allocation that was not
reallocated to the Madison GP (“Deferred Performance Allocation”) will not be
allocated to the Madison GP until the next fiscal year that there is sufficient amount of
Master Fund net profits allocated to the Capital Account even if no performance
allocation is otherwise due in such subsequent fiscal year. Unallocated Deferred
Performance Allocation will not reduce the value of a Capital Account for purposes of
determining the annual performance allocation in a subsequent fiscal year.
If a shareholder or limited partner subject to a Performance Allocation based on
... |
| Account Minimums and Types of Clients — Form ADV Part 2A (7/1/2026) [Brochure] |
|---|
ITEM 7 – Types of Clients As of the date of this Brochure, Montanova’s Clients consist of private pooled investment vehicles and foreign pooled investment vehicles. Fund Investors may include, but are not limited to; high net worth individuals; pension plans (corporate, state or foreign); sovereign wealth funds; endowments; foundations; banks; pooled investment vehicles (e.g., funds-of- funds); trusts; estates or charitable organizations and corporate or business entities. Each Feeder Fund generally requires a minimum investment of $1 million; however, Montanova (or a Fund’s board of directors if applicable) maintains discretion to accept less than the minimum investment threshold. Montanova requires that all Fund Investors read the confidential private placement memorandum, accompanying documentation and complete a Fund’s respective subscription documents. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Arcutis Biotherapeutics Inc | 0.3 | ||
| Veradermics Inc | 0.3 | ||
| Marika Inc | 0.1 | ||
| Legend Biotech Corp | 0.1 | ||
| Benitec Biopharma Inc | 0.1 | ||
| Nile Therapeutics Inc | 0.1 | ||
| Immatics NV | 0.1 | ||
| Arcus Biosciences Inc | 0.1 | ||
| Psivida Corp | 0.1 | ||
| Arrivent Biopharma Inc | 0.1 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Averill Madison Master Fund Ltd | [2023-02-09] | 45.4 M | 807.7 M |
| Filed 2025-11-03 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| VC | Averill Opportunities Offshore Fund I LP | [2021-03-29] | 14.9 M | 0.1 M |
| Filed 2021-01-13 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | Averill Master Fund Ltd | [2020-03-26] | 594.4 M | 4,308.6 M |
| Filed 2026-03-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Suvretta Long Master Fund Ltd | [2017-01-18] | 42.0 M | 2.3 M |
| Filed 2022-06-29 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Suvretta Master Fund Ltd | [2012-09-28] | 619.2 M | 2,702.2 M |
| Filed 2025-06-13 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 10 | 7.9 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 10 | 7.9 |
| By Discretionary | ||
| Discretionary | 10 | 7.9 |
| Non-Discretionary | 0 | 0.0 |
| Total | 10 | 7.9 |
| By Non-United States Persons | ||
| Non-United States Persons | 7.9 | |
| United States Persons | 0.0 | |
| Total | 10 | 7.9 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| William Shaw | Director | 93 | 23 | |
| Tammy Seymour | Director | 48 | 20 | |
| Sherri Fleming | Director | 53 | 12 | |
| Glenn Mitchell | Director | 32 | 12 | |
| T Mitchell | Director | 29 | 11 | |
| Suvretta Capital Management LLC | Executive Officer | 8 | 2 | |
| Aaron Cowen | Director, Executive Officer | 5 | 2 | |
| Averill Opportunities LLC | Executive Officer | 2 | 2 | |
| Averill GP LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001569064] | |
| 3 | [0001569064] | |
| 4 | [0001569064] | |
| SC 13D | [0001569064] | |
| SC 13G | [0001569064] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300B4WZUAJTMV4E82 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Averill Master Fund Ltd | |
| Averill Madison Master Fund Ltd | |
| Suvretta Capital Management LLC | |
| Veradermics Inc | |
| Cowen Aaron | |
| Benitec Biopharma Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-06 | Buy | 19,338 | $36.55 | 706,804 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-06 | Buy | 11,183 | $35.97 | 402,253 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-05 | Buy | 16,563 | $39.80 | 659,207 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-05 | Buy | 17,835 | $38.67 | 689,679 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-05 | Buy | 38,771 | $37.63 | 1,458,953 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-05 | Buy | 19,199 | $36.93 | 709,019 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-05 | Buy | 3,832 | $36.07 | 138,220 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 25,908 | $38.09 | 986,836 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 53,344 | $37.11 | 1,979,596 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 3,178 | $38.90 | 123,624 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 10,676 | $34.74 | 370,884 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 10,004 | $34.25 | 342,637 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 14,659 | $36.27 | 531,682 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 4,453 | $38.09 | 169,615 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 9,168 | $37.11 | 340,224 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 2,519 | $36.27 | 91,364 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 1,835 | $34.74 | 63,748 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 1,720 | $34.25 | 58,910 |
|
Veradermics Inc MANE
Common stock, par value $0.00001 per share
|
2026-02-04 | Buy | 18,489 | $38.90 | 719,222 |
|
Benitec Biopharma Inc BNTC
Common stock, par value $0.0001 per share
|
2025-12-29 | Buy | 11,587 | $13.44 | 155,729 |
| showing 20 of 59 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Ironwood Capital Management Corp
✚
|
CA | 8,225.8 M |
|
Wincoram Asset Management LLC
✚
|
TX | 8,186.1 M |
|
Starboard Value LP
✚
|
NY | 8,151.9 M |
|
Overlook Investments Limited
✚
|
8,092.8 M | |
|
Overlook Investments LP
✚
|
8,092.8 M | |
|
Context Capital Management LLC
✚
|
CA | 8,008.2 M |
|
Polunin Capital Partners Limited
✚
|
7,959.6 M | |
|
LoanCore Capital Credit Advisor LLC
✚
|
CT | 7,922.4 M |
|
Kensico Capital Management Corp
✚
|
CT | 7,876.6 M |
|
Sessa Capital IM LP
✚
|
NY | 7,524.2 M |